Orphan Drugs & Rare Diseases

Digital

To fight rare diseases, win the data battle first

Innovation is the key to evolution. In the pharmaceutical space, brilliant advancements have occurred with drugs with large population pools.

Partner Content

Partner Content

Invitation to SMI’s Orphan Drugs & Rare Diseases Conference ...

SMi reports: Invitation from conference co-chair released for the 9th Annual Orphan Drugs & Rare Diseases conference, taking place in London this October

Oncology

Interview with Vicky Brown at Pharma USA 2026

Hernexeos and what’s next, with Vicky Brown

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Orphan Drugs &amp; Rare Diseases

Editor's Picks

Orphan Drugs & Rare Diseases